Response to Letter to the Editor Titled "The Impact of Patient Characteristics on Tumor Cell PD-L1 Expression in NSCLC Patients".
| Title: | Response to Letter to the Editor Titled "The Impact of Patient Characteristics on Tumor Cell PD-L1 Expression in NSCLC Patients". |
|---|---|
| Authors: | Boothman AM; Precision Medicine and Genomics, Oncology R&D, AstraZeneca, Cambridge, United Kingdom. Electronic address: Anne-Marie.Boothman@astrazeneca.com.; Walker J; Precision Medicine and Genomics, Oncology R&D, AstraZeneca, Cambridge, United Kingdom. |
| Source: | Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer [J Thorac Oncol] 2019 Sep; Vol. 14 (9), pp. e212-e213. |
| Publication Type: | Letter; Comment |
| Language: | English |
| Journal Info: | Publisher: Elsevier Country of Publication: United States NLM ID: 101274235 Publication Model: Print Cited Medium: Internet ISSN: 1556-1380 (Electronic) Linking ISSN: 15560864 NLM ISO Abbreviation: J Thorac Oncol Subsets: MEDLINE |
| Imprint Name(s): | Publication: 2016- : New York, NY : Elsevier; Original Publication: Hagerstown, MD : Lippincott Williams & Wilkins, c2006- |
| MeSH Terms: | Carcinoma, Non-Small-Cell Lung* ; Lung Neoplasms*; Apoptosis ; B7-H1 Antigen ; Humans ; Programmed Cell Death 1 Receptor |
| Comments: | Comment on: J Thorac Oncol. 2019 Aug;14(8):1390-1399. doi: 10.1016/j.jtho.2019.04.025.. (PMID: 31063864); Comment on: J Thorac Oncol. 2019 Sep;14(9):e211. doi: 10.1016/j.jtho.2019.05.034.. (PMID: 31445743) |
| Substance Nomenclature: | 0 (B7-H1 Antigen); 0 (Programmed Cell Death 1 Receptor) |
| Entry Date(s): | Date Created: 20190826 Date Completed: 20200423 Latest Revision: 20200423 |
| Update Code: | 20260130 |
| DOI: | 10.1016/j.jtho.2019.06.022 |
| PMID: | 31445744 |
| Database: | MEDLINE |
Letter; Comment